Ovca1, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality

Genes Chromosomes Cancer. 2008 Apr;47(4):315-25. doi: 10.1002/gcc.20535.

Abstract

In this study, we show genetic modifier genes of Tp53 that can exacerbate embryonic abnormalities. Using a mouse model in which CE/J mice were crossed with the Tp53-null 129/Sv (129-Trp53(tm1 Tyj)) mice, a subset of Tp53+/- and -/- male and female embryos died during gestation. Our hypothesis, based on the genotypes of survivors, is that two genetic modifiers and a Tp53 null allele lead to an increase in embryonic lethality. We previously identified a recessive modifier (Mop1) from CE/J mice on chromosome 11 centromeric to Tp53. We have uncovered a dominant modifier (Mop2) from 129/Sv mice telomeric to Tp53. We discovered a polymorphic change (321P-->321S) of Ovca1 within the Mop2 locus of CE/J mice. This polymorphism increased both mRNA and protein levels of OVCA1 in various tissues. CE/J primary cells cultured from different tissues proliferated more rapidly than 129/Sv cells. In addition, CE/J cells cycled while 129/Sv cells had a higher arrest in the G1 phase. Transfection of Ovca1 containing the 321P polymorphism into CE/J cells caused a higher G1 arrest. The pattern of OVCA1 expression also changed from being diffuse throughout the cytoplasm in 129/Sv cells to being punctuate in the cytoplasm of CE/J cells. Tp53+/- abnormal embryos had more proliferating cells than normal embryos, but no obvious difference in differentiated neuronal cells. Tp53-/- small embryos had less differentiated neuronal cells and proliferating cells than normal embryos. Thus, a polymorphism of Ovca1, combined with Mop1, genetically modifies embryonic lethality in Tp53 deficient mice.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Basic Helix-Loop-Helix Transcription Factors / genetics*
  • Blotting, Western
  • Cell Cycle
  • Cell Proliferation
  • Chromosome Mapping
  • Female
  • Fluorescent Antibody Technique
  • Genes, Lethal*
  • Genetic Markers
  • Genotype
  • Li-Fraumeni Syndrome / genetics*
  • Li-Fraumeni Syndrome / pathology
  • Male
  • Mice
  • Minor Histocompatibility Antigens
  • Mutagenesis, Site-Directed
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Suppressor Protein p53 / genetics*
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism*

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • DPH1 protein, human
  • Genetic Markers
  • Minor Histocompatibility Antigens
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • endothelial PAS domain-containing protein 1